Physician profile
Bryan Q Dang
NPI 1619991742
$395.62
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $279 · 2020: $52.95 · 2021: $22.22 · 2022: $12.97 · 2024: $28.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $28.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $28.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $58.89 | 2019 | |
| Fresenius USA Marketing, INC. | $48.30 | 2019-2020 | |
| Amgen INC. | $45.91 | 2019 | |
| Daiichi Sankyo INC. | $37.24 | 2019-2020 | |
| Boston Scientific Corporation | $28.16 | 2024 | Wavewriter Alpha Prime 16 |
| Eurofins Viracor, LLC | $22.22 | 2021 | |
| Janssen Pharmaceuticals, INC | $21.56 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $20.07 | 2019 | |
| Arbor Pharmaceuticals, INC. | $18.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.46 | 2019 | |
| Vifor Pharma, INC. | $16.62 | 2019 | |
| Akebia Therapeutics INC | $16.47 | 2019 | |
| Mallinckrodt Enterprises LLC | $16.34 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.41 | 2019 | |
| Glaxosmithkline, LLC. | $12.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Dang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.